Mesna Pharmacenter (Mesna)

Mesna is used as a uroprotective adjunct in chemotherapy protocols that involve acrolein‑producing agents.

• Hemorrhagic cystitis associated with cyclophosphamide therapy: reduces incidence and severity of bladder inflammation.
• Hemorrhagic cystitis associated with ifosfamide therapy: provides bladder protection during treatment.
• High‑dose alkylating agent regimens: maintains urinary tract integrity by detoxifying acrolein.

• Mesna delivers sulfhydryl groups that covalently bind the acrolein metabolite formed from cyclophosphamide and ifosfamide. This conjugation neutralizes acrolein's urotoxic activity, preventing it from damaging the bladder epithelium and thereby reducing the risk of hemorrhagic cystitis.

Mesna is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Vomiting: occasional emesis during infusion.
• Headache: transient cranial discomfort.
• Flushing: temporary reddening of skin.
• Metallic taste: brief alteration of taste perception.
• Mild hypotension: slight drop in blood pressure during administration.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical attention.
• Severe hypotension: marked blood pressure decline that may need intervention.
• Pulmonary edema: fluid accumulation in the lungs, a medical emergency.
• Hemolysis: destruction of red blood cells leading to anemia.
• Acute renal failure: sudden loss of kidney function.
• Stevens‑Johnson syndrome: rare severe skin reaction.

When using Mesna, clinicians should consider several safety measures.

• Renal function: assess and monitor patients with impaired kidney function.
• Hepatic function: exercise caution in severe liver disease.
• Timing with chemotherapy: coordinate infusion to coincide with cyclophosphamide or ifosfamide dosing.
• Hypersensitivity: discontinue immediately if allergic reactions develop.
• Pregnancy and lactation: use only if the potential benefit justifies the potential risk.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Mesna may interact with other agents that affect thiol balance or renal clearance.

Major Interactions (Avoid)

• High‑dose N‑acetylcysteine: may diminish Mesna's protective effect.
• Nitrosourea chemotherapy (e.g., carmustine): increased risk of cumulative toxicity.

Moderate Interactions (Monitor Closely)

• Loop diuretics: may enhance renal excretion of Mesna, altering exposure.
• ACE inhibitors: monitor blood pressure as combined hypotensive effects can occur.
• Anticoagulants: observe for any changes in bleeding tendency.
• Other thiol‑containing drugs: assess for additive effects on sulfhydryl pathways.